Citadel Advisors’s enGene Therapeutics ENGN Stock Holding History

Citadel Advisors’s Portfolio ENGN Stock Details ENGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$1.05M	Buy	153,942 +128,559	+506%	+$1.14M	﹤0.01%	7551
2025 Q4	$229K	Sell	25,383 -32,987	-57%	-$264K	﹤0.01%	10736
2025 Q3	$399K	Buy	58,370 +35,327	+153%	+$161K	﹤0.01%	9681
2025 Q2	$83.9K	Buy	+23,043	New	+$86.5K	﹤0.01%	11458
2024 Q3	–	Sell	-613,292	Closed	-$5.78M	–	14454
2024 Q2	$5.78M	Sell	613,292 -190,886	-24%	-$2.45M	﹤0.01%	3521
2024 Q1	$13.6M	Buy	804,178 +784,121	+3,909%	+$9.59M	﹤0.01%	2524
2023 Q4	$185K	Buy	+20,057	New	+$177K	﹤0.01%	10061

Other funds holding ENGN

FIS

FCPM III Services Naarden, Netherlands $722M AUM 73.61% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return

VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return

BOCH

Blue Owl Capital Holdings New York $372M AUM 78.25% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return

Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return

VPC

Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return

MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return

Citadel Advisors's ENGN Position: Q1 2026 in Review

Citadel Advisors increased its enGene Therapeutics (ENGN) stake by 506% in Q1 2026, buying an estimated $1.14M and bringing the position to 153,942 shares worth $1.05M. The position accounts for ﹤0.01% of the portfolio, ranked #7551.

Citadel Advisors first reported a position in ENGN in Q4 2023 and has held it in 7 quarters since. The position peaked at $13.6M in Q1 2024. 61 funds tracked by Wall St. Rank hold ENGN as of Q1 2026.

Citadel Advisors held 153,942 shares of enGene Therapeutics worth $1.05M as of Q1 2026.
Citadel Advisors bought 128,559 enGene Therapeutics shares in Q1 2026, an estimated $1.14M.
enGene Therapeutics made up ﹤0.01% of Citadel Advisors's portfolio in Q1 2026, its #7551 holding.
Citadel Advisors first reported a position in enGene Therapeutics in Q4 2023 and has held it in 7 quarters since.
Citadel Advisors's enGene Therapeutics position peaked at $13.6M in Q1 2024.
61 funds tracked by Wall St. Rank held enGene Therapeutics as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.